CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.

Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A federal judge in Boston Wednesday found the Trump administration violated his preliminary injunction barring third-country removals of migrants without due process, after immigration lawyers say the ...

Tesla's AI-driven future and autonomous advancements could drive a $2T valuation by 2026. Discover why Wedbush's Ives sees a ...